A randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of oral intake of HB05P on improving muscle strength

INTERVENTION: Dietary Supplement : Participants who meet the inclusion and exclusion criteria will be randomly assigned to either the intervention group or the placebo group and will receive HB05P or the placebo once daily for 12 weeks, at a dose of one capsule (430 mg) per intake CONDITION: Diseases of the musculoskeletal system and connective tissue PRIMARY OUTCOME: Changes in quadriceps and hamstring muscle strength(left and right) SECONDARY OUTCOME: Changes in Appendicular Skeletal Muscle Mass/height² Changes in Appendicular Skeletal Muscle Mass/weight X100 Changes in blood biomarkers Changes in Body fat percentage(total, trunk) Changes in grip strength Changes in Lower extremity muscle mass Changes in muscle power Changes in Skeletal Muscle Mass Changes in Total score and individual component scores of Short Physical Performance Battery INCLUSION CRITERIA: 1. Adult men or women aged 60 years or older and under 80 years who meet the inclusion criteria and do not meet any of the exclusion criteria 2. Individuals with a Body Mass Inde X(BMI) between 18.5 and 30.0 kg/m² 3. Individuals with skeletal muscle mass less than 110% of the standard value, as measured by Bioelectrical Impedance Analysis (BIA) 4. Individuals whose handgrip strength of the dominant hand meets the following age‐ and sex‐specific criteria: ‐ 60–69 years: = 38.5 kg for men, = 24.1 kg for women ‐ 70–79 years: = 33.2 kg for men, = 20.9 kg for women 5. Individuals who are capable of normal physical activity and have provided written informed consent to participate in this study